Experienced Biopharmaceutical Industry Executive Adds to the Depth of the Company’s Board
SAN DIEGO, June 17, 2014 (GLOBE NEWSWIRE) — Sente Inc., a privately held specialty aesthetics company pioneering the development of differentiated skincare products based on the science of glycoproteins, announced today that it has appointed Mireille Gillings, Ph.D. to its Board of Directors. Dr. Gillings is Sente’s sixth director and brings additional biotechnology industry operations and management experience to the Sente Board of Directors.
Dr. Gillings has more than 20 years experience in the biotechnology industry and is a published academic in the field of neuroscience. In 2004 she founded HUYA Bioscience International and has since grown this privately-held company to become the global leader in accelerating the co-development of biopharmaceutical product opportunities originating in China. Dr. Gillings was the first to establish extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to create value in worldwide markets for China-sourced novel biopharmaceutical compounds.
Dr. Gillings is a board member of Quintiles, a Fortune 500 company; the vice-chair and co-founder of GHO Capital, a private equity fund specialized in global health; and also serves on the Pasteur Institute Advisory Board. She completed post-doctoral fellowships at Bordeaux University, Scripps Research Institute and holds a Ph.D. from Radboud University Nijmegen.
“We are extremely pleased to have Mireille join our Board during this exciting stage of the company’s growth,” said Faheem Hasnain, Chairman of the Board of Directors of Sente, Inc. “Given Mireille’s extensive knowledge and proven track record in the development of biotechnology companies, she will be a valuable addition to the Sente Board.”
“I am delighted to be associated with Sente’s impressive Board of Directors and management team and I share the commitment to build a leading science based aesthetic skin care company,” said Mireille Gillings, Ph.D. “The proprietary heparan sulfate technology and the impressive customer results clearly differentiate Sente within the growing aesthetic market.”
About Senté, Inc.
Sente, Inc., a privately held specialty aesthetics company, is a recognized leader in the development of innovative and targeted skincare products utilizing HSA technology, a low molecular weight formulation of heparan sulfate. HSA is essential for skin hydration, rejuvenation and necessary for healthy-looking skin. Sente was founded in 2007 and is based in San Diego, California. Further information may be found at http://sentelabs.com/. Sente products are available through an exclusive network of physicians, medically supervised spas.